<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05090124</url>
  </required_header>
  <id_info>
    <org_study_id>GN18MH540</org_study_id>
    <nct_id>NCT05090124</nct_id>
  </id_info>
  <brief_title>Experimental Medicine Studies of Brain and Peripheral Immune Mechanisms for Sickness Behaviours in Patients With Rheumatoid Arthritis</brief_title>
  <acronym>REALISE</acronym>
  <official_title>Experimental Medicine Studies of Brain and Peripheral Immune Mechanisms for Sickness Behaviours in Patients With Rheumatoid Arthritis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>NHS Greater Glasgow and Clyde</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Glasgow</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>NHS Greater Glasgow and Clyde</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The rationale for this study is to use immune molecule-specific drug treatment to leverage a&#xD;
      mechanistic understanding of the brain changes that drive sickness behaviour. This will&#xD;
      combine current therapy with innovative neuroimaging technologies to obtain data in humans&#xD;
      that has hitherto only been available in animal studies. Data supporting the role of&#xD;
      inflammatory molecules in sickness behaviours and other cognitive disorders are increasingly&#xD;
      compelling. A putative mechanism linking inflammatory proteins to sickness behaviour is&#xD;
      Tumour Necrosis Factor (TNF)-driven increases in extracellular glutamate leading to changes&#xD;
      in neural function and brain network integrity and ultimately to sickness behaviour.&#xD;
      Investigators hypothesise that TNF antagonism will effect changes in brain network&#xD;
      connectivity and sickness behaviour score, that Rheumatoid Arthritis (RA) patients will show&#xD;
      changes in brain network connectivity and glutamate quantification in the brain and that RA&#xD;
      patients will show changes in monocyte infiltration into the brain that are correlated with&#xD;
      changes in sickness behaviours. This is a randomised, placebo-controlled waiting list study.&#xD;
      All patients will be eligible for anti-TNF treatment i.e. moderate to severe active disease&#xD;
      as defined by Physician. Participants will be randomised to immediate (fast tracked)&#xD;
      treatment or to treatment after 6-8 weeks (the routine waiting time). The latter group will&#xD;
      receive placebo during the treatment phase.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study will involve participants aged over 18 years with RA and are scheduled to start&#xD;
      outpatient anti-TNF treatment (with Adalimumab) as part of standard clinical care, who meet&#xD;
      the inclusion criteria and none of the specified exclusion criteria. All will give full&#xD;
      informed consent. This is a single-blind, randomised placebo-controlled waiting list study&#xD;
      and after screening and consent, eligible participants will be randomised (1:1) to receive&#xD;
      either adalimumab or placebo.&#xD;
&#xD;
      The study comprises standard care screening for anti-TNF therapy (incorporated into the study&#xD;
      to allow us to fast track screening), a total of 7 research visits and one remote visit via&#xD;
      telephone. At Visit 1 (Day 0) and Visit 5 (Day 42), participants will undergo 7T MRI and MRS&#xD;
      Neuroimaging protocols that incorporate resting-state and task-based fMRI and glutamate MRS&#xD;
      measures. At Visit 2 (Day 1) and Visit 6 (Day 43), participants will undergo a SPECT scanning&#xD;
      protocol. This visit will involve a 160ml blood draw, from which monocytes will be isolated&#xD;
      and radiolabelled before being reinjected prior to SPECT scanning.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 1, 2022</start_date>
  <completion_date type="Anticipated">December 31, 2025</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2025</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Participants will be randomised 1:1 to receive adalimumab or placebo. Upon exiting the study, those in the treatment arm will continue to receive adalimumab without delay and those in the placebo arm will begin adalimumab therapy under NHS standard of care.</intervention_model_description>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Single (Participant)</masking>
    <masking_description>This is a single-blind study, participants will be blinded to their study arm throughout.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Change in sickness score as measured using the sickness questionnaire from baseline to Day 42 following TNF antagonism in RA</measure>
    <time_frame>Baseline and Day 42</time_frame>
    <description>The sickness questionnaire is a 10-item instrument used to capture perceived sickness behaviour. It was developed to display sensitivity to an inflammatory challenge and have adequate psychometric properties.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in brain connectivity as measured by 7T MRI from baseline to Day 42 following TNF antagonism in RA</measure>
    <time_frame>Baseline and Day 42</time_frame>
    <description>Changes in dorsal attention network (DAN) - left inferior parietal lobule (LIPL) brain connectivity as measured by 7T MRI</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in brain glutamate quantification as measured by 7T MRS from baseline to Day 42 following TNF antagonism in RA</measure>
    <time_frame>Baseline and Day 42</time_frame>
    <description>Changes in glutamate quantification in the brain as measured by 7T MRS</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in verbal fluency from baseline to Day 42</measure>
    <time_frame>Baseline and Day 42</time_frame>
    <description>Verbal fluency, measured by F-A-S test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in monocyte infiltration into the brain measured using SPECT in RA</measure>
    <time_frame>Day 1 and Day 43 (monocyte infiltration)</time_frame>
    <description>Change in monocyte infiltration will be measured using SPECT imaging at Day 1 and Day 43</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in measures of RA disease indices with anti-TNF treatment</measure>
    <time_frame>Baseline, Day 14, Day 28 and Day 42</time_frame>
    <description>RA disease activity measured by Disease Activity Score 28</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in fatigue from baseline to Day 42</measure>
    <time_frame>Baseline and Day 42</time_frame>
    <description>Fatigue, measured by BRAF severity / PROMIS-Fatigue.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Hyperalgesia from baseline to Day 42</measure>
    <time_frame>Baseline and Day 42</time_frame>
    <description>Hyperalgesia, measured by the ACR Fibromyalgia Scale.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in pain from baseline to Day 42</measure>
    <time_frame>Baseline and Day 42</time_frame>
    <description>Pain, measured by Visual Analogue Scale-Pain / McGill Pain Questionnaire / Michigan Body Map Regional Pain Intensity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in sleep disturbance from baseline to Day 42</measure>
    <time_frame>Baseline and Day 42</time_frame>
    <description>Sleep disturbance, measured by PROMIS-Sleep related impairment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in mood from baseline to Day 42</measure>
    <time_frame>Baseline and Day 42</time_frame>
    <description>Mood, measured by HADS / PROMIS-Depression / PROMIS-Anxiety.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in processing speed from baseline to Day 42</measure>
    <time_frame>Baseline and Day 42</time_frame>
    <description>Processing Speed, measured by Symbol Digit Modalities Test.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in memory from baseline to Day 42</measure>
    <time_frame>Baseline and Day 42</time_frame>
    <description>Memory, measured by Auditory Verbal Learning Test.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation between changes in primary outcome measures</measure>
    <time_frame>Baseline and Day 42</time_frame>
    <description>Relationship between changes in primary outcome measures, sickness score, brain connectivity and glutamate</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <arm_group>
    <arm_group_label>anti-TNF treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Adalimumab 40mg, will be administered as a subcutaneous injection once fortnightly on four occasions. No dose adjustments are permitted. The actual Adalimumab product selected at site will be dictated by what is used in standard care.&#xD;
The single-use, pre-filled syringe will be removed from storage at 2-8oC at least 30 minutes prior to administration to allow the contents to come to room temperature. The pre-filled syringe will be visually inspected for discolouration and particulates as per the product Summary of Product Characteristics.To facilitate maintenance of the blind, the pre-filled syringe (PFS) presentation will be used. The pen presentation will not be used.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Sodium chloride 0.9% for injection will be used as a placebo to adalimumab. An equal volume will be drawn up into a suitable sized syringe and labelled in accordance with standard practice at site. The dose will be administered as a subcutaneous injection once fortnightly on four occasions. No dose adjustments are permitted. Prior to administration, the prepared placebo syringe will be visually inspected for discolouration and particulate matter prior to administration.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Adalimumab</intervention_name>
    <description>Adalimumab 40mg, will be administered as a subcutaneous injection once fortnightly on four occasions. The actual Adalimumab product selected at site will be dictated by what is used in standard care.</description>
    <arm_group_label>anti-TNF treatment</arm_group_label>
    <other_name>Humira</other_name>
    <other_name>Amgevita</other_name>
    <other_name>Imraldi</other_name>
    <other_name>Hyrimoz</other_name>
    <other_name>Hulio</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Sodium chloride 0.9% for injection will be used as a placebo. An equal volume will be drawn up into a suitable sized syringe and labelled in accordance with standard practice at site. The dose will be administered as a subcutaneous injection once fortnightly on four occasions.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adults â‰¥ 18 years &lt; 75 years.&#xD;
&#xD;
          -  Physician diagnosed moderate to severe RA.&#xD;
&#xD;
          -  No previous biologic disease modifying antirheumatic drug therapy&#xD;
&#xD;
          -  Eligible for anti-TNF treatment in line with site local requirements and selected to&#xD;
             start adalimumab by their usual rheumatology clinical team for active RA in line with&#xD;
             the license for adalimumab (originator or biosimilar) and local practice&#xD;
&#xD;
          -  Self-reported sickness behaviour (fatigue, depression, anxiety) with one component &gt; 4&#xD;
             on NRS&#xD;
&#xD;
          -  Right-handed (to reduce neuroimaging heterogeneity).&#xD;
&#xD;
          -  No contraindications to MRI (e.g. metal implants, claustrophobia).&#xD;
&#xD;
          -  No contraindications to Adalimumab.&#xD;
&#xD;
          -  Agree to use of contraception for study duration, where appropriate.&#xD;
&#xD;
          -  Willing to participate and give informed consent.&#xD;
&#xD;
          -  Satisfactory completion of standard pre-biologic safety screening (including but not&#xD;
             limited to exclusion of latent TB infection according to local protocol, chest X-ray,&#xD;
             negative HIV screen, negative Hepatitis screen antibody, negative Hepatitis B surface&#xD;
             antigen [Hep B sAg] and negative Hepatitis B anit-core antibody [Hep B cAb]&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Inability to provide written informed consent.&#xD;
&#xD;
          -  Severe physical impairment (e.g. blindness, deafness, paraplegia).&#xD;
&#xD;
          -  Pregnant, planning pregnancy or breast feeding.&#xD;
&#xD;
          -  Serious infection including sepsis, tuberculosis and opportunistic infections such as&#xD;
             invasive fungal infections.&#xD;
&#xD;
          -  Severe liver or renal disease.&#xD;
&#xD;
          -  Haemoglobin less than 100g/L&#xD;
&#xD;
          -  Major confounding neurological disease including Multiple Sclerosis, Stroke, Traumatic&#xD;
             Brain Injury, Parkinson's Disease, Alzheimer's Disease&#xD;
&#xD;
          -  Previous biologic disease modifying antirheumatic drug therapy with adalimumab,&#xD;
             etanercept, qolimumab, infliximab, certolizumab, abatacept, tocilizumab, sarilumab,&#xD;
             rituximab, tofacitinib or upadacitinib&#xD;
&#xD;
          -  Recent (within 4 weeks) use of intra-muscular or intra-articular steroid injections&#xD;
&#xD;
          -  History of age-related cognitive impairment or dementia, of any severity&#xD;
&#xD;
          -  Any other medicinal product that may, in the Principal Investigator's opinion,&#xD;
             influence underlying disease activity through effects on immune and/or inflammatory&#xD;
             responses&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>74 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jonathan Cavanagh, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Glasgow</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Alison McColl, PhD</last_name>
    <phone>0141 330 4741</phone>
    <email>alison.mccoll@glasgow.ac.uk</email>
  </overall_contact>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>July 20, 2021</study_first_submitted>
  <study_first_submitted_qc>October 21, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 22, 2021</study_first_posted>
  <last_update_submitted>October 21, 2021</last_update_submitted>
  <last_update_submitted_qc>October 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Sickness Behaviour</keyword>
  <keyword>Tumour Necrosis Factor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
    <mesh_term>Illness Behavior</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adalimumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

